Outcomes of Acute Ischemic Stroke Among Patients with Renal Cell Carcinoma: A Nationwide Analysis.

INTRODUCTION: Renal cell carcinoma (RCC) has been associated with an increased risk for acute ischemic stroke (AIS). As individuals with cancer who experience AIS tend to face higher mortality rates compared to AIS patients without cancer, recognizing the implications of RCC in AIS is crucial for identifying high-risk patients for major complications and directing management strategies. OBJECTIVE: To examine risk factors, interventions, and outcomes for patients with AIS stratified by their RCC diagnosis. METHODS: The National Inpatient Sample (NIS) database was queried for the period 2010-2019 using International Classification of Disease 10th Edition (ICD-10) codes for acute ischemic stroke and renal malignancies. We assessed demographic information, comorbidities, and clinical interventions between patients presenting with AIS, with and without renal malignancies. A logistic regression model was employed to further examine mortality outcomes. RESULTS: Among 1,609,817 patients identified with AIS, 2,068 (0.12%) had a concomitant diagnosis of RCC. AIS patients with RCC were older (72.09 yrs. vs. 70.9 yrs., p < 0.01), more often white (72.05% vs. 68.16%, p < 0.01), and had similar stroke severity scores. RCC patients received less tissue plasminogen activator (tPA; 4.98% vs. 6.2%, p = 0.02) but underwent endovascular mechanical thrombectomy (MT) at similar rates. RCC patients had more complications (p < 0.01) as well as longer hospital stays (8.19 days vs. 5.98 days, p < 0.01), and higher rates of mortality (11.27% vs. 5.63%, p < 0.01), when compared to their non-RCC counterparts. Propensity score-adjusted analysis largely confirmed these findings, with RCC being positively associated with in-hospital mortality (OR: 1.373, p < 0.01) and longer stays (OR: 2.591, p < 0.01). CONCLUSION: In addition to describing the demographics and clinical course of AIS patients diagnosed with RCC, our study underscores the substantial impact of RCC on AIS outcomes. Despite experiencing strokes of similar severity, AIS patients diagnosed with RCC are at a heightened risk of complications, including thromboembolic events and infections, leading to elevated in-hospital mortality rates and prolonged hospital stays.

Modern Sedation and Analgesia Strategies in Neurocritical Care.

PURPOSE OF REVIEW: Patients with acute neurologic injury require a specialized approach to critical care, particularly with regard to sedation and analgesia. This article reviews the most recent advances in methodology, pharmacology, and best practices of sedation and analgesia for the neurocritical care population. RECENT FINDINGS: In addition to established agents such as propofol and midazolam, dexmedetomidine and ketamine are two sedative agents that play an increasingly central role, as they have a favorable side effect profile on cerebral hemodynamics and rapid offset can facilitate repeated neurologic exams. Recent evidence suggests that dexmedetomidine is also an effective component when managing delirium. Combined analgo-sedation with low doses of short-acting opiates is a preferred sedation strategy to facilitate neurologic exams as well as patient-ventilator synchrony. Optimal care for patients in the neurocritical care population requires an adaptation of general ICU strategies that incorporates understanding of neurophysiology and the need for close neuromonitoring. Recent data continues to improve care tailored to this population.

LA ADAPTACIÓN DE LA HEMOGLOBINA Y LOS GLOBULOS BLANCOS EN CASOS SEVEROS DE SARS-COV-2 / THE ADAPTATION OF HEMOGLOBIN AND WHITE BLOOD CELLS IN SEVERE CASES OF SARS-COV-2

Dado que el SARS-CoV-2 causa alteraciones en los parámetros hematológicos, muchos estudios se han concentrado en esta área y los han correlacionado con la gravedad de la enfermedad. Se revisó en un estudio retrospectivo de casos graves de COVID-19, en el cual se contabilizaron y documentaron los datos de hemoglobina (Hb) y glóbulos blancos (WBC) de pacientes reclutados en el período de marzo a julio de 2021. Retrospectivamente, los datos extraídos fueron sobre el nivel de Hb y los recuentos de glóbulos blancos de los informes de laboratorio tanto al ingreso como cuando alta de los pacientes. Se calcularon las frecuencias de anemia o eritrocitopenia (Hb <12 g/dL) y leucocitosis (WBC >11×103/µL) en la población estudiada. De 3637 casos de SARS-COV-2, 250 pacientes con condiciones graves de COVID-19 según la definición de la OMS, ingresaron en la UCI o fallecieron, De 250, 80 (32%) ingresaron a UCI, y el resto 170 casos (68%) fallecieron. Mientras que la edad media de los pacientes fue de 55,46±17,49 años, los pacientes con la condición grave tuvieron significativamente mayor edad que aquellos con la condición leve-moderada (edad media de 50,68 frente a 68,59; P: <0,01). El número medio de glóbulos blancos (WBC) fue de 8,88±7,29 x109/L en todos los pacientes con SARS-COV-2, que es significativamente mayor en los casos graves en comparación con aquellos con enfermedad leve-moderada (10,56 frente a 8,95; P: <0,01). El nivel de Hb (<12 g/dL) fue más bajo en el COVID-19 grave que en otros grupos; sin embargo, no fue estadísticamente significativo. El aumento del número de glóbulos blancos y la disminución de la Hb durante la hospitalización de pacientes con SARS-COV-2, puede predecir un mal resultado. Llegamos a la conclusión de que no sólo el número medio de glóbulos blancos era significativamente mayor en los casos severos también la leucocitosis fue un hallazgo común; lo que indica que un mayor número de glóbulos blancos probablemente puede predecir un mal resultado. Asimismo, el nivel de La Hb fue mayor en el grupo leve-moderado; sin embargo, no fue estadísticamente significativo.

SARS-CoV-2 cause alterations in the hematological parameters and many studies have concentrated on this area and correlated these with severity of disease. A retrospective study of severe cases of COVID-19 were reviewed. The data of hemoglobin (Hb) and white blood cells (WBCs) were accounted and documented. Patients recruited at period from March to July, 2021. Retrospectively, data extracted on the Hb level and WBC counts from Lab reports both at admission and when patients discharge. The frequencies of anemia or erythrocytopenia (Hb <12 g/dL) and leukocytosis (WBC >11×103/µL) was calculated in the studied population. Of 3637 SARS-COV-2 cases, 250 patients with severe conditions of COVID-19 as de ne by WHO, which were either admitted to ICU or died. Of 250, 80(32%) were entered to ICU, and the rest 170 cases (68%) who died. While the mean age of the patients was 55.46±17.49 years, patients with the severe condition were signi cantly older than those with the mildmoderate condition (mean age of 50.68 vs. 68.59; P: <0.01). The mean number of white blood cells (WBC) was 8.88±7.29 x109/L in all SARS-COV-2 patients, which is signi cantly higher in the severe cases compared to those with the mild-moderate disease (10.56 vs. 8.95; P: <0.01). The Hb level (<12 g/ dL) was lower in the severe COVID-19 than other groups; however, it was not statistically signi cant. Increased number of WBCs and dropped Hb level during hospitalization of SARS-COV-2 patients may predict a poor outcome. We concluded that not only the mean number of WBCs was signi cantly higher in the severe cases also leukocytosis was a common nding; indicating that an increased number of WBCs may probably predict a poor outcome. Also, the level of Hb was higher in the mild-moderate group; however, it was not statistically signi cant.